Alembic Pharmaceuticals Ltd

Alembic Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Alembic Pharmaceuticals Ltd

₹ 998 4.12%
25 Apr 4:05 p.m.
alembic-india.com BSE: 533573 NSE : APLLTD
About

Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients.
The company has 3 R&D and 5 manufacturing facilities.

Key Points

Leading Pharma company[1] Alembic is among the top 25 players in domestic formulations market. The company has a portfolio of about 200 formulation brands, of which three are among the top 300 domestic formulation brands in India. It has a share of 1.5% in the domestic market.

Website BSE NSE
  • Market Cap ₹ 19,755 Cr.
  • Current Price ₹ 998
  • High / Low ₹ 1,094 / 537
  • Stock P/E 33.2
  • Book Value ₹ 228
  • Dividend Yield 0.80 %
  • ROCE 7.10 %
  • ROE 7.14 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has been maintaining a healthy dividend payout of 35.5%

Cons

  • Stock is trading at 4.37 times its book value
  • The company has delivered a poor sales growth of 11.8% over past five years.
  • Tax rate seems low
  • Company has a low return on equity of 13.9% over last 3 years.
  • Debtor days have increased from 62.4 to 85.2 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
1,236 1,157 1,270 1,202 1,238 1,318 1,177 1,354 1,310 1,307 1,332 1,479 1,588
864 857 993 986 979 1,152 1,152 1,109 1,086 1,138 1,167 1,271 1,251
Operating Profit 372 300 277 216 259 166 26 245 224 169 166 207 337
OPM % 30% 26% 22% 18% 21% 13% 2% 18% 17% 13% 12% 14% 21%
3 25 2 20 15 12 1 0 1 2 12 9 3
Interest 2 2 2 5 4 6 9 12 15 14 14 15 15
Depreciation 38 42 43 54 56 122 67 67 66 74 66 67 69
Profit before tax 334 281 233 176 214 50 -49 167 144 84 98 134 257
Tax % 17% 18% 17% 19% 17% 16% 0% 12% 17% -55% 0% 0% 9%
277 231 193 143 177 42 -49 146 119 131 98 134 233
EPS in Rs 14.11 11.76 9.80 7.28 8.99 2.11 -2.51 7.45 6.06 6.64 4.96 6.81 11.87
Raw PDF
Upcoming result date: 9 May 2024

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
1,374 1,493 1,844 2,019 3,009 2,986 2,945 3,660 4,133 5,067 5,035 5,149 5,707
1,166 1,249 1,485 1,611 2,026 2,353 2,313 2,782 2,930 3,618 4,127 4,484 4,827
Operating Profit 209 244 359 408 983 633 633 879 1,203 1,449 909 665 880
OPM % 15% 16% 19% 20% 33% 21% 21% 24% 29% 29% 18% 13% 15%
13 13 4 3 7 3 7 6 125 84 51 3 26
Interest 38 24 10 3 4 3 2 15 25 13 17 49 58
Depreciation 34 35 40 44 72 83 102 106 136 183 285 273 276
Profit before tax 150 198 312 363 914 550 535 765 1,167 1,338 658 346 572
Tax % 20% 21% 24% 21% 24% 22% 21% 20% 17% 18% 17% -0%
121 157 238 287 699 431 422 611 969 1,097 544 347 595
EPS in Rs 6.39 8.35 12.64 15.20 37.06 22.84 22.38 32.42 51.42 55.79 27.65 17.64 30.28
Dividend Payout % 22% 30% 24% 23% 11% 18% 18% 17% 19% 25% 36% 45%
Compounded Sales Growth
10 Years: 13%
5 Years: 12%
3 Years: 8%
TTM: 11%
Compounded Profit Growth
10 Years: 8%
5 Years: -4%
3 Years: -29%
TTM: 131%
Stock Price CAGR
10 Years: 13%
5 Years: 12%
3 Years: 0%
1 Year: 82%
Return on Equity
10 Years: 22%
5 Years: 18%
3 Years: 14%
Last Year: 7%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 38 38 38 38 38 38 38 38 38 39 39 39 39
Reserves 323 422 592 796 1,493 1,830 2,157 2,675 3,308 5,062 5,251 4,375 4,447
353 187 109 194 0 8 622 1,059 1,687 584 706 710 853
277 352 423 484 651 634 862 777 846 958 1,078 1,006 997
Total Liabilities 991 999 1,162 1,511 2,182 2,509 3,678 4,549 5,879 6,643 7,074 6,130 6,337
268 344 397 489 697 799 918 1,085 1,276 1,774 1,771 2,377 2,591
CWIP 58 32 21 83 92 348 741 1,107 1,570 2,183 2,304 601 478
Investments 3 3 33 33 37 103 299 506 833 343 219 229 231
661 619 711 906 1,355 1,259 1,720 1,850 2,199 2,344 2,779 2,922 3,037
Total Assets 991 999 1,162 1,511 2,182 2,509 3,678 4,549 5,879 6,643 7,074 6,130 6,337

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
125 274 263 180 848 327 305 809 540 1,388 545 730
-56 -67 -111 -199 -292 -511 -794 -754 -822 -837 -369 -461
-45 -229 -151 18 -276 -96 498 80 166 -534 -217 -261
Net Cash Flow 24 -21 1 -1 280 -280 9 135 -116 18 -40 8

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 50 57 52 61 45 57 77 54 69 30 72 85
Inventory Days 150 148 159 195 240 237 274 325 375 376 339 280
Days Payable 105 130 144 162 225 177 246 173 137 148 139 131
Cash Conversion Cycle 94 75 66 95 60 117 105 207 307 258 272 234
Working Capital Days 62 52 50 69 57 84 109 80 129 102 130 131
ROCE % 29% 33% 47% 41% 72% 32% 23% 24% 27% 25% 12% 7%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
69.48% 69.48% 69.48% 69.61% 69.61% 69.61% 69.61% 69.61% 69.61% 69.61% 69.61% 69.61%
6.41% 5.52% 5.89% 6.02% 5.94% 5.32% 4.99% 4.55% 4.34% 4.51% 4.52% 4.46%
11.25% 11.42% 11.61% 11.74% 12.15% 12.55% 12.76% 13.32% 13.65% 14.22% 14.51% 15.39%
12.86% 13.58% 13.03% 12.63% 12.30% 12.52% 12.64% 12.53% 12.39% 11.67% 11.36% 10.54%
No. of Shareholders 1,01,6861,23,0591,10,0381,06,4371,01,4571,03,8111,01,86499,52297,60789,55285,21276,567

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls